Owing to the recent approval of therapies, such as Elzonris®, Pluvicto®, there has been a substantial increase in the R&D activity to evaluate the use of novel antibody therapy candidates for the treatment of a variety of disease indications
Roots Analysis has announced the addition of “Novel Antibody Therapies Market, 2022-2035” report to its list of offerings.
Antibodies are the key components of immune system that bind to specific markers on cells or tissues, thereby offering first line of defense against multiple disorders. This has opened a new target space for the development of antibody therapeutics and techniques, facilitating tools to uniquely distinct malignantly transformed cells from regular cells.
Key Market Insights
Presently, 140+ novel antibody therapies have been marketed / are being evaluated across different phases of development for the treatment of various disease indications
Till date, five novel antibody therapies have been marketed and close to 80% of the pipeline candidates are under clinical evaluation. It is worth mentioning that most of the drug candidates are immunotoxins (34%), followed by immunocytokines (32.5%). Majority of these therapies are under clinical trials for the treatment of lymphoma (22) followed by solid tumors (19) and leukemia (18).
Around 60 industry and non-industry players are engaged in the development of novel antibody therapies, globally
North America has emerged as the hub, featuring the presence of approximately 60% developers. The market is currently dominated by the presence of small players (27%). Interestingly, 16% of the players are big pharma companies engaged in the development of such therapeutics for multiple target indications.
More than 550 clinical trials have been registered for the evaluation of novel antibody therapies, worldwide
The clinical research activity, in terms of number of trials registered, is reported to have increased at a steady CAGR of 8%, during the period 2016-2021. Of the total number of trials registered, close to 60% have already been completed, while 25% of the studies are actively recruiting participants.
Close to 600 articles related to novel antibody therapies, have been published in reputed scientific journals, since 2017
More than 95% of the articles focused on novel antibody therapies were published post-2019. Popular journals that have published multiple articles include Cancer, Frontiers in Immunology, International Journal of Molecular Sciences and Scientific Reports.
Over 4,600 patents have been filed / granted related to novel antibody therapies, since 2017
More than 1,150 patents were filed / granted in 2021. Further, around 56% of the patents were filed in North America. It is worth highlighting that majority of the patents were granted / filed by prominent industry / non-Industry players, such as Novartis, Hoffmann la Roche, Immatics Biotechnologies and Pfizer.
Partnership activity in this field has increased at a CAGR of over 55%, since 2018
Around 50% of the reported deals were established post-2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that majority of the agreements were supply agreements (19%), followed by product development and commercialization agreements (15%).
North America is anticipated to capture larger share of the phase III novel antibody therapies market by 2035
Around 40% of the market revenues are likely to be generated from the sales of drug candidates being evaluated in phase III for bladder cancer. Further, therapies designed for intravenous route of administration are expected to occupy close to 70% of the overall market.
Key Questions Answered
- Who are the leading industry and non-industry players engaged in the development of novel antibody therapies?
- Which novel antibody therapies are being developed across early and late stages of development?
- Which geographies are the most active in conducting clinical trials related to novel antibody therapies?
- What is the focus area of various publications related to the novel antibody therapies?
- Which are the leading funding institutes / centers supporting the research related to novel antibody therapies?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What are the different initiatives undertaken by big pharma players for the development of novel antibody therapies in the recent past?
- How is the current and future market opportunity, related to novel antibody therapies likely to be distributed across key market segments?
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Target disease Indication(s)
- Acute Myeloid Leukemia
- Advanced / Metastatic soft-tissue sarcoma
- Melanoma
- Diffuse Large B-cell Lymphoma
- Bladder Cancer
- Prostate Cancer
- Graft-versus-host disease
Type of Novel Antibody
- Immunocytokines
- Immunotoxins
- Radioisotope immunoconjugates
Type of Therapy
- Combination Therapy
- Monotherapy
- Route of Administration
- Intravenous
- Intravesical
- Intratumoral
Geographical Region
- North America
- Europe
- Asia-Pacific
Key companies covered in the report
- Actinium Pharmaceuticals
- Molecular Templates
- Philogen
- Roche
- Seagen
- Sesen bio
- Telix Pharmaceuticals
- Y-mAbs Therapeutics
